• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows CGMs better at controlling blood sugar in type 2 diabetes

June 3, 2021 By Sean Whooley

CGMs Diabetes 21st Century Dexcom Medtronic Abbott SenseonicsKaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes.

The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study was published yesterday in JAMA and was supported by an independent investigator award from Dexcom and funding from the National Institute of Diabetes and Digestive and Kidney Diseases.

The retrospective, comparative effectiveness study observed 5,673 patients with type 1 diabetes and 36,080 patients with type 2 diabetes treated with insulin who were self-monitoring glucose. On the recommendation of their doctors, 3,462 of the type 1 patients and 344 of the type 2 patients began using CGMs between January 2015 and December 2019, according to a news release.

Researchers evaluated before-and-after results for patients who initiated CGM use against those who did not by using statistical techniques mimicking clinical trial randomization. The analysis demonstrated that the CGMs were associated with a decline in levels of HbA1c and a reduction in emergency department visits and hospitalizations for hypoglycemia.

“The improvement in blood sugar control was comparable to what a patient might experience after starting a new diabetes medication,” the study’s lead author, Kaiser Permanente senior research scientist Andrew J. Karter, said in the release.

Researchers say the next step is to determine if there are other type 2 diabetes patients whose blood sugar would be better and more safely controlled with CGMs.

“This study found that patients who used continuous glucose monitors had very good results compared to those who continued only with intermittent testing using finger sticks,” senior author and endocrinologist Dr. Richard Dlott said. “We now need to determine whether there are other patients who might also benefit, even if they don’t meet all of the Medicare criteria. The newest technology isn’t always better for everybody. We need to identify the people who are most likely to benefit.”

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring Tagged With: CGM, Dexcom, Diabetes, kaiserpermanente

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS